证券时报网络版郑重声明经证券时报社授权，证券时报网独家全权代理《证券时报》信息登载业务。本页内容未经书面授权许可，不得转载、复制或在非证券时报网所属服务器建立镜像。欲咨询授权事宜请与证券时报网联系 (0755-83501827) 。 |
深圳市海普瑞药业股份有限公司公告（系列） 2013-12-27 来源：证券时报网 作者：
交易对方承诺与声明 致：深圳市海普瑞药业股份有限公司 深圳市海普瑞药业股份有限公司（“买方”）拟根据买方、SPL Acquisition Corp.（“目标公司”）、目标公司的全体股东以及作为股东代表的American Capital, Ltd于2013年12月26日签署的股权收购协议（“收购协议”）向包括American Capital, Ltd.在内的目标公司全体股东购买其持有的全部SPL Acquisition Corp.股权。 受制于收购协议的约定，作为本次交易的卖方之一，American Capital, Ltd.特此向买方陈述和保证：就其所知，其以目标公司的股东身份为本次交易所提供给买方的全部信息均为真实、准确和完整的，不存在虚假记载、误导性陈述或者重大遗漏。 To: Shenzhen Hepalink Pharmaceutical Co., Ltd. Pledge and statement of Seller to Buyer in the transaction Shenzhen Hepalink Pharmaceutical Co., Ltd. (“Buyer”) intends to purchase all the equity interest of SPL Acquisition Corp. (the “Target Company”) held by American Capital, Ltd. and other shareholders of the Target Company pursuant to that certain Stock Purchase Agreement (the “Purchase Agreement”) dated as of [__DEC 26th_], 2013 among Buyer, the Target Company, the shareholders of the Target Company and American Capital, Ltd., as the Stockholder Representative. Subject to the terms of the Purchase Agreement, as a Seller in this transaction, American Capital, Ltd. represents and warrants to Buyer that all of the information provided by American Capital, Ltd. to Buyer in connection with the transaction solely in its capacity as an equity holder of the Target Company is, to the knowledge of American Capital, Ltd., true, accurate and complete, without any false record, misleading statement or major omission. American Capital, Ltd. 授权代表签字 (By)： Signature of Authorized Representative 姓名 (Name): ______________________ 职务 (Title): _______________________ 日期 (Date): _______________________
交易对方承诺与声明 致：深圳市海普瑞药业股份有限公司 深圳市海普瑞药业股份有限公司（“买方”）拟根据买方、SPL Acquisition Corp.（“目标公司”）、目标公司的全体股东以及作为股东代表的American Capital, Ltd于2013年12月26日签署的股权收购协议（“收购协议”）向包括American Capital Equity I, LLC 在内的目标公司全体股东购买其持有的全部SPL Acquisition Corp.股权。 受制于收购协议的约定，作为本次交易的卖方之一，American Capital Equity I, LLC特此向买方陈述和保证：就其所知，其以目标公司的股东身份为本次交易所提供给买方的全部信息均为真实、准确和完整的，不存在虚假记载、误导性陈述或者重大遗漏。 To: Shenzhen Hepalink Pharmaceutical Co., Ltd. Pledge and statement of Seller to Buyer in the transaction Shenzhen Hepalink Pharmaceutical Co., Ltd. (“Buyer”) intends to purchase all the equity interest of SPL Acquisition Corp. (the “Target Company”) held by American Capital Equity I, LLC and other shareholders of the Target Company pursuant to that certain Stock Purchase Agreement (the “Purchase Agreement”) dated as of [_DEC 26th_], 2013 among Buyer, the Target Company, the shareholders of the Target Company and American Capital, Ltd., as the Stockholder Representative. Subject to the terms of the Purchase Agreement, as a Seller in this transaction, American Capital Equity I, LLC represents and warrants to Buyer that all of the information provided by American Capital Equity I, LLC to Buyer in connection with the transaction solely in its capacity as an equity holder of the Target Company is, to the knowledge of American Capital Equity I, LLC, true, accurate and complete, without any false record, misleading statement or major omission. American Capital Equity I, LLC American Capital Equity Management I, LLC作为其管理人 By: American Capital Equity Management I, LLC Its: Manager 授权代表签字 (By)： Signature of Authorized Representative 姓名 (Name): ______________________ 职务 (Title): _______________________ 日期 (Date): _______________________
交易对方承诺与声明 致：深圳市海普瑞药业股份有限公司 深圳市海普瑞药业股份有限公司（“买方”）拟根据买方、SPL Acquisition Corp.（“目标公司”）、目标公司的全体股东以及作为股东代表的American Capital, Ltd于2013年12月26日签署的股权收购协议（“收购协议”）向包括American Capital Equity II, LP 在内的目标公司全体股东购买其持有的全部SPL Acquisition Corp.股权。 受制于收购协议的约定，作为本次交易的卖方之一，American Capital Equity II, LP特此向买方陈述和保证：就其所知，其以目标公司的股东身份为本次交易所提供给买方的全部信息均为真实、准确和完整的，不存在虚假记载、误导性陈述或者重大遗漏。 To: Shenzhen Hepalink Pharmaceutical Co., Ltd. Pledge and statement of Seller to Buyer in the transaction Shenzhen Hepalink Pharmaceutical Co., Ltd. (“Buyer”) intends to purchase all the equity interest of SPL Acquisition Corp. (the “Target Company”) held by American Capital Equity II, LP and other shareholders of the Target Company pursuant to that certain Stock Purchase Agreement (the “Purchase Agreement”) dated as of [_DEC 26th_], 2013 among Buyer, the Target Company, the shareholders of the Target Company and American Capital, Ltd., as the Stockholder Representative. Subject to the terms of the Purchase Agreement, as a Seller in this transaction, American Capital Equity II, LP represents and warrants to Buyer that all of the information provided by American Capital Equity II, LP to Buyer in connection with the transaction solely in its capacity as an equity holder of the Target Company is, to the knowledge of American Capital Equity II, LP, true, accurate and complete, without any false record, misleading statement or major omission. American Capital Equity II, LP American Capital Equity Management II, LLC作为其管理人 By: American Capital Equity Management II, LLC Its: General Partner 授权代表签字 (By)： Signature of Authorized Representative 姓名 (Name): ______________________ 职务 (Title): _______________________ 日期 (Date): _______________________
交易对方承诺与声明 致：深圳市海普瑞药业股份有限公司 深圳市海普瑞药业股份有限公司（“买方”）拟根据买方、SPL Acquisition Corp.（“目标公司”）、目标公司的全体股东以及作为股东代表的American Capital, Ltd于2013年12月26日签署的股权收购协议（“收购协议”）向包括American Capital, Ltd.在内的目标公司全体股东购买其持有的全部SPL Acquisition Corp.股权。 受制于收购协议的约定，作为本次交易的卖方之一，Cathy Jo Halpin特此向买方陈述和保证：就本人所知，本人以目标公司的股东身份为本次交易所提供给买方的关于本人及本人持有SPL股权情况的全部信息均为真实、准确和完整的，不存在虚假记载、误导性陈述或者重大遗漏。 To: Shenzhen Hepalink Pharmaceutical Co., Ltd. Pledge and statement of Seller to Buyer in the transaction Shenzhen Hepalink Pharmaceutical Co., Ltd. (“Buyer”) intends to purchase all the equity interest of SPL Acquisition Corp. (the “Target Company”) held by American Capital, Ltd. and other shareholders of the Target Company pursuant to that certain Stock Purchase Agreement (the “Purchase Agreement”) dated as of [_DEC 26th_], 2013 among Buyer, the Target Company, the shareholders of the Target Company and American Capital, Ltd., as the Stockholder Representative. Subject to the terms of the Purchase Agreement, as a Seller in this transaction, Cathy Jo Halpin represents and warrants to Buyer that all of the information provided by myself regarding the shares in SPL held by myself and the personal information to Buyer solely in my capacity as an equity holder of the Target Company is, to the knowledge of myself, true, accurate and complete, without any false record, misleading statement or major omission. _______________________ Cathy Jo Halpin 日期Date:
交易对方承诺与声明 致：深圳市海普瑞药业股份有限公司 深圳市海普瑞药业股份有限公司（“买方”）拟根据买方、SPL Acquisition Corp.（“目标公司”）、目标公司的全体股东以及作为股东代表的American Capital, Ltd于2013年12月26日签署的股权收购协议（“收购协议”）向包括American Capital, Ltd.在内的目标公司全体股东购买其持有的全部SPL Acquisition Corp.股权。 受制于收购协议的约定，作为本次交易的卖方之一，Daniel William Groskreutz特此向买方陈述和保证：就本人所知，本人以目标公司的股东身份为本次交易所提供给买方的关于本人及本人持有SPL股权情况的全部信息均为真实、准确和完整的，不存在虚假记载、误导性陈述或者重大遗漏。 To: Shenzhen Hepalink Pharmaceutical Co., Ltd. Pledge and statement of Seller to Buyer in the transaction Shenzhen Hepalink Pharmaceutical Co., Ltd. (“Buyer”) intends to purchase all the equity interest of SPL Acquisition Corp. (the “Target Company”) held by American Capital, Ltd. and other shareholders of the Target Company pursuant to that certain Stock Purchase Agreement (the “Purchase Agreement”) dated as of [_DEC 26th_], 2013 among Buyer, the Target Company, the shareholders of the Target Company and American Capital, Ltd., as the Stockholder Representative. Subject to the terms of the Purchase Agreement, as a Seller in this transaction, Daniel William Groskreutz represents and warrants to Buyer that all of the information provided by myself regarding the shares in SPL held by myself and the personal information to Buyer solely in my capacity as an equity holder of the Target Company is, to the knowledge of myself, true, accurate and complete, without any false record, misleading statement or major omission. _______________________ Daniel William Groskreutz 日期Date:
交易对方承诺与声明 致：深圳市海普瑞药业股份有限公司 深圳市海普瑞药业股份有限公司（“买方”）拟根据买方、SPL Acquisition Corp.（“目标公司”）、目标公司的全体股东以及作为股东代表的American Capital, Ltd于2013年12月26日签署的股权收购协议（“收购协议”）向包括American Capital, Ltd.在内的目标公司全体股东购买其持有的全部SPL Acquisition Corp.股权。 受制于收购协议的约定，作为本次交易的卖方之一，David Gaylen Strunce特此向买方陈述和保证：就本人所知，本人以目标公司的股东身份为本次交易所提供给买方的关于本人及本人持有SPL股权情况的全部信息均为真实、准确和完整的，不存在虚假记载、误导性陈述或者重大遗漏。 To: Shenzhen Hepalink Pharmaceutical Co., Ltd. Pledge and statement of Seller to Buyer in the transaction Shenzhen Hepalink Pharmaceutical Co., Ltd. (“Buyer”) intends to purchase all the equity interest of SPL Acquisition Corp. (the “Target Company”) held by American Capital, Ltd. and other shareholders of the Target Company pursuant to that certain Stock Purchase Agreement (the “Purchase Agreement”) dated as of [_DEC 26th_], 2013 among Buyer, the Target Company, the shareholders of the Target Company and American Capital, Ltd., as the Stockholder Representative. Subject to the terms of the Purchase Agreement, as a Seller in this transaction, David Gaylen Strunce represents and warrants to Buyer that all of the information provided by myself regarding the shares in SPL held by myself and the personal information to Buyer solely in my capacity as an equity holder of the Target Company is, to the knowledge of myself, true, accurate and complete, without any false record, misleading statement or major omission. _______________________ David Gaylen Strunce 日期Date:
交易对方承诺与声明 致：深圳市海普瑞药业股份有限公司 深圳市海普瑞药业股份有限公司（“买方”）拟根据买方、SPL Acquisition Corp.（“目标公司”）、目标公司的全体股东以及作为股东代表的American Capital, Ltd于2013年12月26日签署的股权收购协议（“收购协议”）向包括American Capital, Ltd.在内的目标公司全体股东购买其持有的全部SPL Acquisition Corp.股权。 受制于收购协议的约定，作为本次交易的卖方之一，Francisco Calvo特此向买方陈述和保证：就本人所知，本人以目标公司的期权持有者身份为本次交易所提供给买方的关于本人及本人持有SPL期权情况的全部信息均为真实、准确和完整的，不存在虚假记载、误导性陈述或者重大遗漏。 To: Shenzhen Hepalink Pharmaceutical Co., Ltd. Pledge and statement of Seller to Buyer in the transaction Shenzhen Hepalink Pharmaceutical Co., Ltd. (“Buyer”) intends to purchase all the equity interest of SPL Acquisition Corp. (the “Target Company”) held by American Capital, Ltd. and other shareholders of the Target Company pursuant to that certain Stock Purchase Agreement (the “Purchase Agreement”) dated as of [_DEC 26th_], 2013 among Buyer, the Target Company, the shareholders of the Target Company and American Capital, Ltd., as the Stockholder Representative. Subject to the terms of the Purchase Agreement, as a Seller in this transaction, Francisco Calvo represents and warrants to Buyer that all of the information provided by myself regarding the stock options in SPL held by myself and the personal information to Buyer solely in my capacity as an option holder of the Target Company is, to the knowledge of myself, true, accurate and complete, without any false record, misleading statement or major omission. _______________________ Francisco Calvo 日期Date:
交易对方承诺与声明 致：深圳市海普瑞药业股份有限公司 深圳市海普瑞药业股份有限公司（“买方”）拟根据买方、SPL Acquisition Corp.（“目标公司”）、目标公司的全体股东以及作为股东代表的American Capital, Ltd于2013年12月26日签署的股权收购协议（“收购协议”）向包括American Capital, Ltd.在内的目标公司全体股东购买其持有的全部SPL Acquisition Corp.股权。 受制于收购协议的约定，作为本次交易的卖方之一，Gregg R Steinhauer特此向买方陈述和保证：就本人所知，本人以目标公司的股东身份为本次交易所提供给买方的关于本人及本人持有SPL股权情况的全部信息均为真实、准确和完整的，不存在虚假记载、误导性陈述或者重大遗漏。 To: Shenzhen Hepalink Pharmaceutical Co., Ltd. Pledge and statement of Seller to Buyer in the transaction Shenzhen Hepalink Pharmaceutical Co., Ltd. (“Buyer”) intends to purchase all the equity interest of SPL Acquisition Corp. (the “Target Company”) held by American Capital, Ltd. and other shareholders of the Target Company pursuant to that certain Stock Purchase Agreement (the “Purchase Agreement”) dated as of [_DEC 26th_], 2013 among Buyer, the Target Company, the shareholders of the Target Company and American Capital, Ltd., as the Stockholder Representative. Subject to the terms of the Purchase Agreement, as a Seller in this transaction, Gregg R Steinhauer represents and warrants to Buyer that all of the information provided by myself regarding the shares in SPL held by myself and the personal information to Buyer solely in my capacity as an equity holder of the Target Company is, to the knowledge of myself, true, accurate and complete, without any false record, misleading statement or major omission. _______________________ Gregg R Steinhauer 日期Date:
交易对方承诺与声明 致：深圳市海普瑞药业股份有限公司 深圳市海普瑞药业股份有限公司（“买方”）拟根据买方、SPL Acquisition Corp.（“目标公司”）、目标公司的全体股东以及作为股东代表的American Capital, Ltd于2013年12月26日签署的股权收购协议（“收购协议”）向包括American Capital, Ltd.在内的目标公司全体股东购买其持有的全部SPL Acquisition Corp.股权。 受制于收购协议的约定，作为本次交易的卖方之一，Kathleen Ann Lynch特此向买方陈述和保证：就本人所知，本人以目标公司的股东身份为本次交易所提供给买方的关于本人及本人持有SPL股权情况的全部信息均为真实、准确和完整的，不存在虚假记载、误导性陈述或者重大遗漏。 To: Shenzhen Hepalink Pharmaceutical Co., Ltd. Pledge and statement of Seller to Buyer in the transaction Shenzhen Hepalink Pharmaceutical Co., Ltd. (“Buyer”) intends to purchase all the equity interest of SPL Acquisition Corp. (the “Target Company”) held by American Capital, Ltd. and other shareholders of the Target Company pursuant to that certain Stock Purchase Agreement (the “Purchase Agreement”) dated as of [_DEC 26th_], 2013 among Buyer, the Target Company, the shareholders of the Target Company and American Capital, Ltd., as the Stockholder Representative. Subject to the terms of the Purchase Agreement, as a Seller in this transaction, Kathleen Ann Lynch represents and warrants to Buyer that all of the information provided by myself regarding the shares in SPL held by myself and the personal information to Buyer solely in my capacity as an equity holder of the Target Company is, to the knowledge of myself, true, accurate and complete, without any false record, misleading statement or major omission. _______________________ Kathleen Ann Lynch 日期Date:
交易对方承诺与声明 致：深圳市海普瑞药业股份有限公司 深圳市海普瑞药业股份有限公司（“买方”）拟根据买方、SPL Acquisition Corp.（“目标公司”）、目标公司的全体股东以及作为股东代表的American Capital, Ltd于2013年12月26日签署的股权收购协议（“收购协议”）向包括American Capital, Ltd.在内的目标公司全体股东购买其持有的全部SPL Acquisition Corp.股权。 受制于收购协议的约定，作为本次交易的卖方之一，Kenneth Scott Manning特此向买方陈述和保证：就本人所知，本人以目标公司的股东身份为本次交易所提供给买方的关于本人及本人持有SPL股权情况的全部信息均为真实、准确和完整的，不存在虚假记载、误导性陈述或者重大遗漏。 To: Shenzhen Hepalink Pharmaceutical Co., Ltd. Pledge and statement of Seller to Buyer in the transaction Shenzhen Hepalink Pharmaceutical Co., Ltd. (“Buyer”) intends to purchase all the equity interest of SPL Acquisition Corp. (the “Target Company”) held by American Capital, Ltd. and other shareholders of the Target Company pursuant to that certain Stock Purchase Agreement (the “Purchase Agreement”) dated as of [_DEC 26th_], 2013 among Buyer, the Target Company, the shareholders of the Target Company and American Capital, Ltd., as the Stockholder Representative. Subject to the terms of the Purchase Agreement, as a Seller in this transaction, Kenneth Scott Manning represents and warrants to Buyer that all of the information provided by myself regarding the shares in SPL held by myself and the personal information to Buyer solely in my capacity as an equity holder of the Target Company is, to the knowledge of myself, true, accurate and complete, without any false record, misleading statement or major omission. _______________________ Kenneth Scott Manning 日期Date:
交易对方承诺与声明 致：深圳市海普瑞药业股份有限公司 深圳市海普瑞药业股份有限公司（“买方”）拟根据买方、SPL Acquisition Corp.（“目标公司”）、目标公司的全体股东以及作为股东代表的American Capital, Ltd于2013年12月26日签署的股权收购协议（“收购协议”）向包括American Capital, Ltd.在内的目标公司全体股东购买其持有的全部SPL Acquisition Corp.股权。 受制于收购协议的约定，作为本次交易的卖方之一，Kevin Richard Tebrinke特此向买方陈述和保证：就本人所知，本人以目标公司的股东身份为本次交易所提供给买方的关于本人及本人持有SPL股权情况的全部信息均为真实、准确和完整的，不存在虚假记载、误导性陈述或者重大遗漏。 To: Shenzhen Hepalink Pharmaceutical Co., Ltd. Pledge and statement of Seller to Buyer in the transaction Shenzhen Hepalink Pharmaceutical Co., Ltd. (“Buyer”) intends to purchase all the equity interest of SPL Acquisition Corp. (the “Target Company”) held by American Capital, Ltd. and other shareholders of the Target Company pursuant to that certain Stock Purchase Agreement (the “Purchase Agreement”) dated as of [_DEC 26th_], 2013 among Buyer, the Target Company, the shareholders of the Target Company and American Capital, Ltd., as the Stockholder Representative. Subject to the terms of the Purchase Agreement, as a Seller in this transaction, Kevin Richard Tebrinke represents and warrants to Buyer that all of the information provided by myself regarding the shares in SPL held by myself and the personal information to Buyer solely in my capacity as an equity holder of the Target Company is, to the knowledge of myself, true, accurate and complete, without any false record, misleading statement or major omission. _______________________ Kevin Richard Tebrinke 日期 Date:
交易对方承诺与声明 致：深圳市海普瑞药业股份有限公司 深圳市海普瑞药业股份有限公司（“买方”）拟根据买方、SPL Acquisition Corp.（“目标公司”）、目标公司的全体股东以及作为股东代表的American Capital, Ltd于2013年12月26日签署的股权收购协议（“收购协议”）向包括American Capital, Ltd.在内的目标公司全体股东购买其持有的全部SPL Acquisition Corp.股权。 受制于收购协议的约定，作为本次交易的卖方之一，Michael Joseph Reardon特此向买方陈述和保证：就本人所知，本人以目标公司的股东身份为本次交易所提供给买方的关于本人及本人持有SPL股权情况的全部信息均为真实、准确和完整的，不存在虚假记载、误导性陈述或者重大遗漏。 To: Shenzhen Hepalink Pharmaceutical Co., Ltd. Pledge and statement of Seller to Buyer in the transaction Shenzhen Hepalink Pharmaceutical Co., Ltd. (“Buyer”) intends to purchase all the equity interest of SPL Acquisition Corp. (the “Target Company”) held by American Capital, Ltd. and other shareholders of the Target Company pursuant to that certain Stock Purchase Agreement (the “Purchase Agreement”) dated as of [_DEC 26th_], 2013 among Buyer, the Target Company, the shareholders of the Target Company and American Capital, Ltd., as the Stockholder Representative. Subject to the terms of the Purchase Agreement, as a Seller in this transaction, Michael Joseph Reardon represents and warrants to Buyer that all of the information provided by myself regarding the shares in SPL held by myself and the personal information to Buyer solely in my capacity as an equity holder of the Target Company is, to the knowledge of myself, true, accurate and complete, without any false record, misleading statement or major omission. _______________________ Michael Joseph Reardon 日期Date:
交易对方承诺与声明 致：深圳市海普瑞药业股份有限公司 深圳市海普瑞药业股份有限公司（“买方”）拟根据买方、SPL Acquisition Corp.（“目标公司”）、目标公司的全体股东以及作为股东代表的American Capital, Ltd于2013年12月26日签署的股权收购协议（“收购协议”）向包括American Capital, Ltd.在内的目标公司全体股东购买其持有的全部SPL Acquisition Corp.股权。 受制于收购协议的约定，作为本次交易的卖方之一，Robert George Garreau特此向买方陈述和保证：就本人所知，本人以目标公司的股东身份为本次交易所提供给买方的关于本人及本人持有SPL股权情况的全部信息均为真实、准确和完整的，不存在虚假记载、误导性陈述或者重大遗漏。 To: Shenzhen Hepalink Pharmaceutical Co., Ltd. Pledge and statement of Seller to Buyer in the transaction Shenzhen Hepalink Pharmaceutical Co., Ltd. (“Buyer”) intends to purchase all the equity interest of SPL Acquisition Corp. (the “Target Company”) held by American Capital, Ltd. and other shareholders of the Target Company pursuant to that certain Stock Purchase Agreement (the “Purchase Agreement”) dated as of [_DEC 26th_], 2013 among Buyer, the Target Company, the shareholders of the Target Company and American Capital, Ltd., as the Stockholder Representative. Subject to the terms of the Purchase Agreement, as a Seller in this transaction, Robert George Garreau represents and warrants to Buyer that all of the information provided by myself regarding the shares in SPL held by myself and the personal information to Buyer solely in my capacity as an equity holder of the Target Company is, to the knowledge of myself, true, accurate and complete, without any false record, misleading statement or major omission. _______________________ Robert George Garreau 日期Date:
交易对方承诺与声明 致：深圳市海普瑞药业股份有限公司 深圳市海普瑞药业股份有限公司（“买方”）拟根据买方、SPL Acquisition Corp.（“目标公司”）、目标公司的全体股东以及作为股东代表的American Capital, Ltd于2013年12月26日签署的股权收购协议（“收购协议”）向包括American Capital, Ltd.在内的目标公司全体股东购买其持有的全部SPL Acquisition Corp.股权。 受制于收购协议的约定，作为本次交易的卖方之一，LEE Robert Johnston Jr特此向买方陈述和保证：就本人所知，本人以目标公司的期权持有者身份为本次交易所提供给买方的关于本人及本人持有SPL股权情况的全部信息均为真实、准确和完整的，不存在虚假记载、误导性陈述或者重大遗漏。 To: Shenzhen Hepalink Pharmaceutical Co., Ltd. Pledge and statement of Seller to Buyer in the transaction Shenzhen Hepalink Pharmaceutical Co., Ltd. (“Buyer”) intends to purchase all the equity interest of SPL Acquisition Corp. (the “Target Company”) held by American Capital, Ltd. and other shareholders of the Target Company pursuant to that certain Stock Purchase Agreement (the “Purchase Agreement”) dated as of [_DEC 26th_], 2013 among Buyer, the Target Company, the shareholders of the Target Company and American Capital, Ltd., as the Stockholder Representative. Subject to the terms of the Purchase Agreement, as a Seller in this transaction, LEE Robert Johnston Jr represents and warrants to Buyer that all of the information provided by myself regarding the stock options in SPL held by myself and the personal information to Buyer solely in my capacity as an option holder of the Target Company is, to the knowledge of myself, true, accurate and complete, without any false record, misleading statement or major omission. _______________________ LEE Robert Johnston Jr 日期Date:
交易对方承诺与声明 致：深圳市海普瑞药业股份有限公司 深圳市海普瑞药业股份有限公司（“买方”）拟根据买方、SPL Acquisition Corp.（“目标公司”）、目标公司的全体股东以及作为股东代表的American Capital, Ltd于2013年12月26日签署的股权收购协议（“收购协议”）向包括American Capital, Ltd.在内的目标公司全体股东购买其持有的全部SPL Acquisition Corp.股权。 受制于收购协议的约定，作为本次交易的卖方之一，Robert Stephen Mills Jr特此向买方陈述和保证：就本人所知，本人以目标公司的股东身份为本次交易所提供给买方的关于本人及本人持有SPL股权情况的全部信息均为真实、准确和完整的，不存在虚假记载、误导性陈述或者重大遗漏。 To: Shenzhen Hepalink Pharmaceutical Co., Ltd. Pledge and statement of Seller to Buyer in the transaction Shenzhen Hepalink Pharmaceutical Co., Ltd. (“Buyer”) intends to purchase all the equity interest of SPL Acquisition Corp. (the “Target Company”) held by American Capital, Ltd. and other shareholders of the Target Company pursuant to that certain Stock Purchase Agreement (the “Purchase Agreement”) dated as of [_DEC 26th_], 2013 among Buyer, the Target Company, the shareholders of the Target Company and American Capital, Ltd., as the Stockholder Representative. Subject to the terms of the Purchase Agreement, as a Seller in this transaction, Robert Stephen Mills Jr represents and warrants to Buyer that all of the information provided by myself regarding the shares in SPL held by myself and the personal information to Buyer solely in my capacity as an equity holder of the Target Company is, to the knowledge of myself, true, accurate and complete, without any false record, misleading statement or major omission. _______________________ Robert Stephen Mills Jr 日期Date:
交易对方承诺与声明 致：深圳市海普瑞药业股份有限公司 深圳市海普瑞药业股份有限公司（“买方”）拟根据买方、SPL Acquisition Corp.（“目标公司”）、目标公司的全体股东以及作为股东代表的American Capital, Ltd于2013年12月26日签署的股权收购协议（“收购协议”）向包括American Capital, Ltd.在内的目标公司全体股东购买其持有的全部SPL Acquisition Corp.股权。 受制于收购协议的约定，作为本次交易的卖方之一，Yan Wang特此向买方陈述和保证：就本人所知，本人以目标公司的股东身份为本次交易所提供给买方的关于本人及本人持有SPL股权情况的全部信息均为真实、准确和完整的，不存在虚假记载、误导性陈述或者重大遗漏。 To: Shenzhen Hepalink Pharmaceutical Co., Ltd. Pledge and statement of Seller to Buyer in the transaction Shenzhen Hepalink Pharmaceutical Co., Ltd. (“Buyer”) intends to purchase all the equity interest of SPL Acquisition Corp. (the “Target Company”) held by American Capital, Ltd. and other shareholders of the Target Company pursuant to that certain Stock Purchase Agreement (the “Purchase Agreement”) dated as of [_DEC 26th_], 2013 among Buyer, the Target Company, the shareholders of the Target Company and American Capital, Ltd., as the Stockholder Representative. Subject to the terms of the Purchase Agreement, as a Seller in this transaction, Yan Wang represents and warrants to Buyer that all of the information provided by myself regarding the shares in SPL held by myself and the personal information to Buyer solely in my capacity as an equity holder of the Target Company is, to the knowledge of myself, true, accurate and complete, without any false record, misleading statement or major omission. _______________________ Yan Wang 日期Date: 本版导读：
发表评论：财苑热评： |
证券时报多媒体数字报
2013年12月27日
按日期查找:
< 上一期 下一期 >
< 上一期 下一期 >
